



Exosome platform: revenue now, regenerative upside later

Scalable exosome technology for services, cosmetics and advanced wound care.

INVESTOR ONEPAGER

Company thesis

Vesicly is building an end-to-end exosome platform designed to solve three bottlenecks in regenerative medicine: scalable production, standardized isolation and stable delivery.

- High-yield 3D MSC culture for industrial-scale production.
- Lyophilized formulations for off-the-shelf stability.
- Hydrogel patch delivery system for sustained local release.

BUSINESS MODEL

Three phases, one platform

1 EaaS

Research-grade EV vials, custom isolation and premium development services for biotech, pharma and cosmetics.


2 Cosmeceuticals

Professional skincare and ingredient partnerships with faster development and lower regulatory burden.

3 Wound care

Exosome-loaded hydrogel patches for chronic wounds and advanced regenerative medicine applications.

Technology platform



Production

High-yield 3D culture



Purification

Breakthrough isolation



Formulation

Off-the-shelf stability

Validation & traction

10x

higher EV yield vs. 2D culture

240+

days ambient stability

10+

LOIs signed

1

paid pilot secured

- Provisional patent filed: US 63/904,174.
- Second patent in development.
- Initial EaaS revenue and paid pilots in negotiation.

Markets

Platform exposure across exosome services, professional cosmetics and advanced wound care.

TAM > USD 104B

EaaS SAM USD 1.5-2.5B

Wound care TAM > USD 22B

Raising

USD 500K


18-24 month runway to GLP setup, EaaS launch, IP filing and first revenue milestones.

Preclinical signal


Wound healing (in vivo) after 48 h




Wound healing (scratch assay)



Migration



Proliferation



Data shown: murine wound closure, scratch assay, migration and proliferation readouts.

Team



Mikela Amondarain, Ph.D.

CEO & Co-Founder

MSC-exosome research, isolation, characterization and regenerative applications.



Carlos Luzzani, Ph.D.

COO & Co-Founder

15+ years in cell and molecular biology; serial healthtech entrepreneur.

Advisors:

Ana Rovetta, Ph.D. (cosmetic R&D)
José Luis Pedraz, Ph.D. (biomaterials)